Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Intrinsic Value
Shanghai RAAS Blood Products Co., Ltd. engages in the research and development, production and sales of blood products. [ Read More ]
The intrinsic value of one Shanghai RAAS Blood Products Co Ltd stock under the Base Case scenario is 10.82 CNY. Compared to the current market price of 7.32 CNY, Shanghai RAAS Blood Products Co Ltd is Undervalued by 32%.
Valuation Backtest
Shanghai RAAS Blood Products Co Ltd
Run backtest to discover the historical profit from buying and selling Shanghai RAAS Blood Products Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Shanghai RAAS Blood Products Co Ltd
| Current Assets | 8.7B |
| Cash & Short-Term Investments | 4.8B |
| Receivables | 715m |
| Other Current Assets | 3.2B |
| Non-Current Assets | 23.4B |
| Long-Term Investments | 17.1B |
| PP&E | 1.3B |
| Intangibles | 4.9B |
| Other Non-Current Assets | 137.7m |
| Current Liabilities | 1.7B |
| Accounts Payable | 1.3B |
| Accrued Liabilities | 130.3m |
| Short-Term Debt | 168.9k |
| Other Current Liabilities | 295.4m |
| Non-Current Liabilities | 13.5m |
| Long-Term Debt | 1.7m |
| Other Non-Current Liabilities | 11.8m |
Earnings Waterfall
Shanghai RAAS Blood Products Co Ltd
|
Revenue
|
7.6B
CNY
|
|
Cost of Revenue
|
-4.4B
CNY
|
|
Gross Profit
|
3.1B
CNY
|
|
Operating Expenses
|
-1.1B
CNY
|
|
Operating Income
|
2B
CNY
|
|
Other Expenses
|
41.7m
CNY
|
|
Net Income
|
2.1B
CNY
|
Free Cash Flow Analysis
Shanghai RAAS Blood Products Co Ltd
Profitability Score
Profitability Due Diligence
Shanghai RAAS Blood Products Co Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Shanghai RAAS Blood Products Co Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shanghai RAAS Blood Products Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Shanghai RAAS Blood Products Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shanghai RAAS Blood Products Co Ltd
According to Wall Street analysts, the average 1-year price target for Shanghai RAAS Blood Products Co Ltd is 9 CNY .
Shareholder Return
Price
Shanghai RAAS Blood Products Co Ltd
| Average Annual Return | -5.07% |
| Standard Deviation of Annual Returns | 4.45% |
| Max Drawdown | -52% |
| Market Capitalization | 49.3B CNY |
| Shares Outstanding | 6 645 480 758 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Shanghai RAAS Blood Products Co., Ltd. engages in the research and development, production and sales of blood products. The company is headquartered in Shanghai, Shanghai and currently employs 2,966 full-time employees. The company went IPO on 2008-06-23. The firm's main products include human albumin and human immunoglobulin for intravenous injection, human coagulation factors and others. The firm is also engaged in the distribution of Chinese medicine products and foods. The firm distributes its products within domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Shanghai RAAS Blood Products Co Ltd stock under the Base Case scenario is 10.82 CNY.
Compared to the current market price of 7.32 CNY, Shanghai RAAS Blood Products Co Ltd is Undervalued by 32%.
You don't have any saved screeners yet
